Patients considering GLP-1 receptor agonist or dual GIP/GLP-1 therapy should understand that these medications facilitate weight loss through appetite reduction and decreased food intake, not by "speeding up metabolism" or burning additional calories at rest
Experiments were performed to characterize the pharmacokinetics, absorption, distribution, metabolism, and excretion characteristics of BPC157 in rats and dogs
Lpez-Padrs C, Salord N, Alves C, et al
Specifically, NAD rejected Willows argument based on physician prescribing practices, stating that an experts conclusory statement or action is of little value and that expert opinions are most reliable when coupled with competent and reliable evidence demonstrating scientific consensus on an issue. NAD also found that studies referenced by Willow concerning the effectiveness of its products for weight loss only involved FDA-approved GLP-1 products and were insufficient to validate claims for compounded alternatives that differ in active pharmaceutical ingredient, formulation or method of administration. Therefore, NAD concluded that Willow did not establish a reasonable basis for its claims and recommended that Willow discontinue or modify its advertising